Hyftor(R) - topical sirolimus 0.2% gel for TSC-related angiofibromas
Please help support EDVYCE by answering this SPONSOR SURVEY QUESTION.
PRIZES:
All respondents will be entered in a raffle to receive one $50 or one of ten $10 US-based Amazon gift cards.
Prizes will be awarded within 2-4 weeks following the deadline date.
DEADLINE:
September 15, 2023
PLEASE SIMPLY CLICK ON YOUR CHOICE (YOU ARE WELCOME TO ADD ANY ADDITIONAL OPTIONAL COMMENTS BELOW)
For TSC-related facial angiofibroma, what is your awareness of Hyftor(R) (sirolimus 0.2% topical), the first & only FDA-approved treatment for this indication
0%A) I was not previously aware of this product
0%B) I am aware of Hyftor(R), but have not yet prescribed it
0%C) I am aware of Hyftor(R), and have prescribed it
For more information about Hyftor(R), please go to www.Hyftor.com
One more week to enter the raffle for prizes.
Please take a moment to click on one of these responses to enter!